Physician profile

Albert Drane Oliphant, IV

Oral and Maxillofacial Surgery · Charleston, SC

NPI 1336302363

$17,727.43

in general payments reported to CMS, 2019-2025

9 companies · $281 in 2025

The $281 reported for 2025 was more than what a typical Oral and Maxillofacial Surgery provider received nationally (typical 2025 total: $150).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,027.78
Debt Forgiveness$1,370.48
Gift$248.63
Entertainment$104.88

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Straumann USA LLC $17,394.30 2019-2025
Dentsply Ih INC. $128.91 2019
Salvin Dental Specialties, INC. $44.25 2020
Biohorizons Implant Systems INC. $40.71 2020
Keystone Dental INC. $39.67 2019
Patterson Companies, INC. $35.37 2025
Acelrx Pharmaceuticals, INC. $16.89 2022
Dentsply Sirona INC $14.14 2019
Kowa Pharmaceuticals America, INC. $13.19 2022

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Albert Drane Oliphant, IV

$17,727.43

in general payments reported 2019-2025

Years
2019-2025
Top company
Straumann USA LLC
Context
The $281 reported for 2025 was more than what a typical Oral and Maxillofacial Surgery provider received nationally (typical 2025 total: $150).

https://glasscript.com/doctor/885103/albert-drane-oliphant

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.